Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: cyclophilin inhibitors - Abliva

Next Previous
X
Search
Drug Profile

Research programme: cyclophilin inhibitors - Abliva

Alternative Names: nPT-CyP; NV 422; NV 556; NVP 024; NVP 025; NVP-022; Sangamides

Latest Information Update: 28 Feb 2022

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biotica Technology
  • Developer Abliva; Arbutus Biopharma; Karolinska Institute
  • Class Macrolides
  • Mechanism of Action Cyclophilin D inhibitors; Cyclophilin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Non-alcoholic steatohepatitis

Highest Development Phases

  • No development reported Liver cancer; Mitochondrial myopathies; Non-alcoholic steatohepatitis
  • Discontinued Hepatitis B; Hepatitis C

Most Recent Events

  • 28 Feb 2022 No recent reports of development identified for preclinical development in Mitochondrial-myopathies in Sweden (PO)
  • 28 Feb 2021 No recent reports of development identified for preclinical development in Liver-cancer in Sweden
  • 28 Dec 2020 No recent reports of development identified for preclinical development in Non-alcoholic-steatohepatitis in Sweden (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top